ArticleScience translational medicine2017
Antimalarial efficacy of MMV390048, an inhibitor of
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 1 pooled it
24.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 1 synthesis or guideline pooled it, 267 citations in OpenAlex.
- Plasmodial Kinase Inhibitors Targeting Malaria: Recent Developments.Molecules (Basel, Switzerland) · 2020Pooled it
- Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria.The American journal of tropical medicine and hygiene · 2023Trial
- Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the NovelAntimicrobial agents and chemotherapy · 2020Trial
- New thinking for the next generation of antimalarials.EMBO molecular medicine · 2026Review
- New thinking for the next generation of antimalarials.EMBO molecular medicine · 2026Review
- Phosphatidylinositol 4-kinase as a target of pathogens-friend or foe?FEBS letters · 2026Review
- Discovery of Sphaeriaurantins as Rapid-Acting Antiplasmodials with Dual Activity in Blood and Liver Stages.Journal of the American Chemical Society · 2026Article
- Advancing global malaria control: therapeutic strategies, drug discovery, and formulation innovations.Infection · 2026Review
- Efficacy, Structure-Activity Relationship, and Mode of Action Studies of a New Generation of Acridine/Acridone-Based Antimalarials.ACS infectious diseases · 2026Article
- Mechanistic perspectives on antimalarial agents: from FDA-approved drugs to next-generation candidates.RSC advances · 2026Review
- Mechanisms of PfDNMT2 inhibition and PfATP6-mediated resistance to the antimalarial candidate SC83288 in Plasmodium falciparum.Nature communications · 2026Article
- Shaping Antimalarials: A Geometry-First Approach toJournal of medicinal chemistry · 2026Article
- Targeting Aurora Kinases as Essential Cell-Cycle Regulators to Deliver Multi-Stage Antimalarials Against Plasmodium Falciparum.Angewandte Chemie (International ed. in English) · 2025Article
- A Novel Antimalarial Agent that Inhibits Protein Synthesis in Plasmodium falciparum.Angewandte Chemie (International ed. in English) · 2025Article
- Addressing infectious diseases in Africa by accelerating drug discovery through data science.Communications medicine · 2025Review
- Optimization of 2,8-Diaryl-1,5-naphthyridines asJournal of medicinal chemistry · 2025Article
- In vitro cultured malaria hypnozoites leave a footprint of specific metabolites.PLoS pathogens · 2025Article
- Novel Inhibitors ofJournal of medicinal chemistry · 2025Article
- Identification of novel compounds with prophylactic activity against hypnozoites using aAntimicrobial agents and chemotherapy · 2025Article
- Characterization of the malaria parasiteMicrobiology spectrum · 2025Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors at 20 institutions in 12 countries.
Tanya PaquetDepartment of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0001-8847-3977
Claire Le ManachDepartment of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Diego González CabreraDepartment of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Yassir YounisDepartment of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Philipp P HenrichDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA.
Tara S AbrahamDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA.ORCID 0000-0002-8250-6384
Marcus C S LeeDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA.
Rajshekhar BasakDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA.ORCID 0000-0002-2531-4589
Sonja Ghidelli-DisseCellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
María José Lafuente-MonasterioMalaria Disease Performance Unit, Tres Cantos Medicines Development Campus, Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain.
Marcus BantscheffCellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
Andrea RueckerDepartment of Life Sciences, Imperial College, London SW7 2AZ, UK.ORCID 0000-0003-3804-9670
Andrew M BlagboroughDepartment of Life Sciences, Imperial College, London SW7 2AZ, UK.
Sara E ZakutanskyDepartment of Life Sciences, Imperial College, London SW7 2AZ, UK.
Anne-Marie ZeemanDepartment of Parasitology, Biomedical Primate Research Centre, 2280 GH Rijswijk, Netherlands.
Karen L WhiteCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
David M ShacklefordCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Janne MannilaCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Julia MorizziCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Christian ScheurerSwiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland.
Iñigo Angulo-BarturenMalaria Disease Performance Unit, Tres Cantos Medicines Development Campus, Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain.
María Santos MartínezMalaria Disease Performance Unit, Tres Cantos Medicines Development Campus, Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain.ORCID 0000-0001-7894-2135
Santiago FerrerMalaria Disease Performance Unit, Tres Cantos Medicines Development Campus, Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain.
Laura María SanzMalaria Disease Performance Unit, Tres Cantos Medicines Development Campus, Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain.
Francisco Javier GamoMalaria Disease Performance Unit, Tres Cantos Medicines Development Campus, Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain.
Janette ReaderDepartment of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria, Pretoria, South Africa.
Mariette BothaDepartment of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria, Pretoria, South Africa.
Koen J DecheringTropIQ Health Sciences, Transistorweg 5, 6534 AT Nijmegen, Netherlands.
Robert W SauerweinTropIQ Health Sciences, Transistorweg 5, 6534 AT Nijmegen, Netherlands.ORCID 0000-0002-3163-7202
Anchalee TungtaengDepartment of Veterinary Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok 10400, Thailand.
Pattaraporn VanachayangkulDepartment of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok 10400, Thailand.
Chek Shik LimNovartis Institute for Tropical Diseases Pte. Ltd., 10 Biopolis Road, #05-01 Chromos, Singapore 138670, Singapore.
Jeremy BurrowsMedicines for Malaria Venture, International Center Cointrin, Route de Pré-Bois 20, 1215 Geneva, Switzerland.
Michael J WittyDepartment of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Kennan C MarshAbbVie, 1 North Waukegan Road, North Chicago, IL 60064-6104, USA.
Christophe BodenreiderNovartis Institute for Tropical Diseases Pte. Ltd., 10 Biopolis Road, #05-01 Chromos, Singapore 138670, Singapore.
Rosemary RochfordDepartments of Immunology and Microbiology and Environmental and Occupational Health, University of Colorado Denver, Aurora, CO 80045, USA.ORCID 0000-0002-0001-5152
Suresh M SolapureNagarjuna Gardens, 60 Feet Road, Sahakaranagar, Bangalore 560092, India.ORCID 0000-0002-6237-8848
María Belén Jiménez-DíazDepartment of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1020 Locust Street, Suite 368, Philadelphia, PA 19107, USA.
Sergio WittlinSwiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland.
Susan A CharmanCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Cristina DoniniMedicines for Malaria Venture, International Center Cointrin, Route de Pré-Bois 20, 1215 Geneva, Switzerland.ORCID 0000-0002-3265-8734
Brice CampoMedicines for Malaria Venture, International Center Cointrin, Route de Pré-Bois 20, 1215 Geneva, Switzerland.
Lyn-Marie BirkholtzDepartment of Biochemistry, Centre for Sustainable Malaria Control, University of Pretoria, Pretoria, South Africa.
Kirsten K HansonDepartment of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, 1 UTSA Circle, San Antonio, TX 78249, USA.ORCID 0000-0002-0154-0979
Gerard DrewesCellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
Clemens H M KockenDepartment of Parasitology, Biomedical Primate Research Centre, 2280 GH Rijswijk, Netherlands.
Michael J DelvesDepartment of Life Sciences, Imperial College, London SW7 2AZ, UK.
Didier LeroyMedicines for Malaria Venture, International Center Cointrin, Route de Pré-Bois 20, 1215 Geneva, Switzerland.
David A FidockDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA.
David WatersonDepartment of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Leslie J StreetDepartment of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0002-1888-6626
Kelly ChibaleDepartment of Chemistry, University of Cape Town, Rondebosch 7701, South Africa. kelly.chibale@uct.ac.za.ORCID 0000-0002-4541-646X
University of Cape Town · ZAGlaxoSmithKline (France) · FRMonash University · AUColumbia University Irving Medical Center · USImperial College London · GBMedicines for Malaria Venture · CHGlaxoSmithKline (Germany) · DEUniversity of Pretoria · ZAArmed Forces Research Institute of Medical Science · THBiomedical Primate Research Centre · NLNovartis (Singapore) · SGSwiss Tropical and Public Health Institute · CHThomas Jefferson University · USAbbVie (United States) · USAcharya Nagarjuna University · INRadboud University Nijmegen · NLSouth African Medical Research Council · ZATexas Center for Infectious Disease · USTropIQ Health Sciences · NLUniversity of Colorado Hospital · US
Funding
PREDOCTORAL PROGRAM IN BIOPHYSICST32GM008283 · NIGMS · YALE UNIVERSITY · PI XIONG, YONG · 1988 to 2022
$10.5MDefining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4MDefining the targets of broad intervention antimalarial agentsR01AI103058 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2013 to 2016
$2.6MMedical Research Council MR/N00227X/1NIAID NIH HHS R01 AI103058NIAID NIH HHS R01 AI109023NIGMS NIH HHS T32 GM008283Wellcome TrustWellcome Trust WT078285
Abstract
As part of the global effort toward malaria eradication, phenotypic whole-cell screening revealed the 2-aminopyridine class of small molecules as a good starting point to develop new antimalarial drugs. Stemming from this series, we found that the derivative, MMV390048, lacked cross-resistance with current drugs used to treat malaria. This compound was efficacious against all
Indexed as
1-Phosphatidylinositol 4-KinaseAminopyridinesAnimalsAntimalarialsFemaleMalariaMaleMiceMice, SCIDParasitic Sensitivity TestsPlasmodiumSulfones1-Phosphatidylinositol 4-Kinasealpha-aminopyridineAminopyridinesAntimalarialsMMV390048Sulfones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.